12,372 trials
Attention Deficit Hyperactivity Disorder (ADHD) · Anxiety Disorders and Symptoms
Primary: The Average Change in the Total Score Across the "Inattention" and "Hyperactivity/Impulsivity" Subscales of the Swanson, Nolan and Pelham Teacher and Parent Rating Scale…
Atrial Fibrillation (AF) · Magnesium Sulfate · Post Cardiac Surgery Patients
Primary: Number of Participants With New Episodes of Atrial Fibrillation — 12; 27 participants
H.Pylori Infection
Primary: Eradication Rate of H.Pylori Infection — 323; 304 Participants
Atrial Fibrillation
Primary: Number of Participants With Any Primary Adverse Events (PAE) That Occurred Within 7 Days Following Atrial Fibrillation (AF) Ablation Procedure Using HELIOSTAR Catheter…
Bleeding Cardiac Surgery Patients
Primary: Number of Patients Requiring Additional Hemostatic Intervention — 166; 125; 47; 82 Participants — p=<0.0001
Ventricular Tachycardia
Primary: Number of Participants With Inducible Sustained Ventricular Tachycardia/ Ventricular Fibrillation (VT/VF) Utilizing Standardized Stimulation Protocol. — 4; 9 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Annualized Rate of Moderate or Severe Exacerbations — 0.80; 1.01 Exacerbations per year — p=0.011
Women at Risk for Pregnancy
Primary: Relative Maximum Observed Total Serum Copper Concentration of VeraCept vs ParaGard (Cmax) — 1210; 1300 ng/mL
Alopecia Areata
Primary: Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit — 401; 515 Participants
Depression
Primary: Remission Rate — 2; 3 Participants — p=0.6
Atopic Dermatitis
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events — 451; 34 Participants
Hypercholesterolemia
Primary: Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150 — -46.54; -11.17; 1.37; -49.37 Percentage change from baseline — p=<0.0001
Dry Eye Disease
Primary: Ocular Treatment-Emergent Adverse Events by Preferred Term With Incidence Greater Than 2 Percent — 90; 7; 2; 3 adverse event
HIV Infections
Primary: Number of Participants With a Composite Safety Endpoint Adverse Event (AE) — 2; 6; 16; 5 Participants
Osteoarthritis
Primary: Least Squares Mean (Standard Error) [LS-mean (SE)] Change From Baseline in WOMAC Pain Subscale Score at Week 12 — -2.959; -2.847 score on a scale